Valuation: Immutep Limited

Market Cap 70.74M 49.47M 43.45M 40.41M 37.08M 69.66M 4.76B 480M 187M 2.34B 186M 182M 8.1B P/E 2026 *
-1.24x
P/E 2027 * -1.77x
Enterprise Value 5.74M 4.01M 3.53M 3.28M 3.01M 5.65M 387M 38.94M 15.21M 190M 15.07M 14.75M 657M EV / Sales 2026 *
0.33x
EV / Sales 2027 * -2.04x
Free-Float
96.98%
Yield 2026 *
-
Yield 2027 * -
1 day-4.00%
1 week-11.11%
Current month-9.43%
1 month-7.69%
3 months-35.14%
6 months-89.57%
Current year-88.43%
1 week 0.05
Extreme 0.048
0.05
1 month 0.05
Extreme 0.048
0.07
Current year 0.03
Extreme 0.028
0.47
1 year 0.03
Extreme 0.028
0.47
3 years 0.03
Extreme 0.028
0.48
5 years 0.03
Extreme 0.028
0.71
10 years 0.03
Extreme 0.028
0.72
Manager TitleAgeSince
Chief Executive Officer 53 09/07/2014
Director of Finance/CFO - 01/03/2018
Chief Tech/Sci/R&D Officer - 01/07/2025
Director TitleAgeSince
Director/Board Member 53 09/07/2014
Chairman 76 17/11/2017
Director/Board Member 57 12/02/2014
Date Insider Type Main position Quantity % Market Cap.
18/03/26 Other

Executive/Senior Manager

5,174,048 0.3511%
18/03/26 Other

Chief Operating Officer

4,667,305 0.3167%
18/03/26 Other

Chief Technology Officer

758,059 0.0514%
Change 5-day change 1-year change 3-year change Capi.($)
-4.00%-11.11%-80.00%-85.23% 51.37M
+1.07%-4.73%-3.96%+11.63% 46.35B
+0.25%+1.65%+408.41%+629.49% 40.13B
-0.27%+4.45%+9.93%+66.92% 36.33B
+0.35%+0.87%+3.60%-8.81% 34.6B
+3.14%+1.02%+3.72%+34.86% 26.77B
+0.47%-2.74% - - 16.66B
-0.73%+11.84%+31.97%+143.53% 16.91B
+0.42%-4.46%+4.80%+8.67% 13.05B
-2.68%-2.49%-15.00%-31.68% 13.05B
Average -0.21%+0.17%+40.39%+85.49% 24.39B
Weighted average by Cap. +0.44%+0.77%+75.66%+136.34%

Financials

2026 *2027 *
Net sales 17.23M 12.05M 10.58M 9.84M 9.03M 16.97M 1.16B 117M 45.67M 571M 45.24M 44.27M 1.97B 3.16M 2.21M 1.94M 1.8M 1.65M 3.11M 213M 21.41M 8.37M 105M 8.29M 8.11M 361M
Net income -58.54M -40.94M -35.95M -33.44M -30.68M -57.65M -3.94B -397M -155M -1.94B -154M -150M -6.7B -47.05M -32.9M -28.9M -26.87M -24.66M -46.33M -3.17B -319M -125M -1.56B -124M -121M -5.39B
Net Debt -65M -45.45M -39.92M -37.13M -34.07M -64.01M -4.38B -441M -172M -2.15B -171M -167M -7.44B -77.18M -53.97M -47.4M -44.08M -40.45M -76.01M -5.2B -523M -205M -2.56B -203M -198M -8.83B
Logo Immutep Limited
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.
Employees
31
Date Price Change Volume
24/07/26 A$0.0480 -4.00% 14,492,733
23/07/26 A$0.0500 0.00% 3,003,770
22/07/26 A$0.0500 +2.04% 16,763,215
21/07/26 A$0.0490 -2.00% 3,550,883
20/07/26 A$0.0500 0.00% 12,370,257
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
0.0480AUD
Average target price
0.1033AUD
Spread / Average Target
+115.27%

Quarterly revenue - Rate of surprise